The big shareholder groups in Lyra Therapeutics, Inc. ( NASDAQ:LYRA ) have power over the company. Institutions will...
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.